How Iwicki was paid
$1.5M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Mark IwickiFormer Chief Executive Officer | $709,394 | $297,945 | $100,100 | $377,628 | $6,120 | $1,491,187 |
| Todd BazemoreFormer Interim Chief Executive Officer, Former President and Chief Operating Officer | $535,600 | $187,460 | $45,500 | $171,543 | $9,447 | $949,550 |
| Kim Brazzell, Ph.D.Head of Research and Development and Chief Medical Officer | $520,000 | $163,800 | $45,500 | $171,543 | $19,844 | $920,687 |
What changed and why
- $1.5MFormer CEO Mark Iwicki received total compensation of $1,491,187 in 2024.
- 70%Discretionary annual bonuses were awarded at 70% of each individual's target bonus opportunity.
- Stock awards granted in 2024 reflected the aggregate grant date fair value of RSUs.
- Option awards were valued using a Black-Scholes option pricing model.
- Settlement agreements in November 2025 provided cash settlement payments in exchange for waiving contractual severance rights.
Other KALA BIO proxy statements
- 2026 proxy statement
Todd Bazemore paid $3.5M (+266% on the year).
Filed Sep 24, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.